News | January 28, 2025
Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Q3 FY25 revenue up 24% to Rs 3,230 crore
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
PAT after MI is Rs. 41 crore which is 162% increase
EBITDA margins expand to 31.3%
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Subscribe To Our Newsletter & Stay Updated
